AURORA: Characterization of HIV-positive treatment-naïve patients under real-life conditions in Germany

• Conditions: B20-B24; Human immunodeficiency virus [HIV] disease

• Registration Number: DRKS00019047
• Lead Sponsor: MSD SHARP & DOHME GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-11-26
• Study Completion: 2020-10-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 355

Inclusion Criteria

1) Confirmed infection with HIV-1 (positive HIV test according to appropriate standard practice [e.g. PCR test])
2) Antiretroviral therapeutic-naïve before the baseline visit
3) Decision on antiretroviral therapy was made before inclusion in the study and prescribed at the baseline visit
4) Baseline visit is a current visit or was not more than 2 years before study start
5) Written informed consent given

Exclusion Criteria

1) Existent contraindication/intolerability against the selected antiretroviral therapy or its components
2) Patients who started their ART before market authorization of the used compound(s) in Germany, e.g. participants of clinical trial(s)
3) Investigator considers patient's available information (especially on concomitant diseases and co-medications) as unreliable or incomplete

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Characterization of the Profile of therapy-naive HIV+ patients starting antivretroviral Treatment.

Secondary Outcome Measures

Name	Time	Method
Comparison of the Profiles of HIV+ patients starting on different antiretroviral therapies.